🇺🇸 FDA
Pipeline program

BGB-A445

BGB-A317-A445-201

Phase 2 small_molecule active

Quick answer

BGB-A445 for Urothelial Carcinoma is a Phase 2 program (small_molecule) at BeOne Medicines with 1 ClinicalTrials.gov record(s).

Program details

Company
BeOne Medicines
Indication
Urothelial Carcinoma
Phase
Phase 2
Modality
small_molecule
Status
active

Clinical trials